| Anteris Technologies Ltd (AVR) CHESS DEPOSITARY INTERESTS 1:1 US PROHIBITED |
Health Care |
$293 |
Board Appointments
|
10 Jun 2025 8:40AM |
$7.000 |
$7.100 |
risen by
1.43%
|
|
| Litchfield Minerals Limited (LMS) ORDINARY FULLY PAID |
Materials |
$23 |
LMS Secures Strong NT backing through 3 exploration grants
|
10 Jun 2025 8:40AM |
$0.110 |
$0.400 |
risen by
263.64%
|
|
LMS - Price-sensitive ASX Announcement
Full Release
Key Points
- Litchfield Minerals Limited (LMS) received three exploration grants from the Northern Territory Government.
- The grants are part of the Geophysics and Drilling Collaborations program.
- Funding will support LMS's critical minerals exploration projects in the Northern Territory.
- Grants reflect strong government support and confidence in LMS’s exploration approach.
- Funds will be used for drilling and geophysical survey activities in priority areas.
- Grants are expected to accelerate LMS’s exploration programs and enhance discovery potential.
- Securing these grants strengthens LMS’s position within the Northern Territory’s minerals sector.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Flight Centre Travel Group Limited (FLT) ORDINARY FULLY PAID |
Consumer Discretionary |
$3,250 |
Update - Notification of buy-back - FLT
|
10 Jun 2025 8:39AM |
$13.170 |
$15.205 |
risen by
15.45%
|
|
| FleetPartners Group Limited (FPR) ORDINARY FULLY PAID |
Financials |
$638 |
Update - Notification of buy-back - FPR
|
10 Jun 2025 8:39AM |
$2.990 |
$2.950 |
fallen by
1.34%
|
|
| Prodigy Gold NL (PRX) ORDINARY FULLY PAID |
Materials |
$19 |
Entitlement Offer Cleansing Notice
|
10 Jun 2025 8:39AM |
$0.003 |
$0.056 |
risen by
2,140%
|
|
| US Masters Residential Property Fund (URF) FULLY PAID UNITS STAPLED SECURITIES |
Real Estate |
$199 |
Update - Notification of buy-back - URF
|
10 Jun 2025 8:39AM |
$0.380 |
$0.288 |
fallen by
24.34%
|
|
| Botanix Pharmaceuticals Ltd (BOT) ORDINARY FULLY PAID |
Health Care |
$232 |
Botanix Signs Debt Facility with Kreos Capital
|
10 Jun 2025 8:39AM |
$0.330 |
$0.118 |
fallen by
64.39%
|
|
BOT - Price-sensitive ASX Announcement
Full Release
Key Points
- Botanix Pharmaceuticals Ltd signed a debt facility agreement with Kreos Capital.
- The facility allows Botanix to draw up to US$40 million in non-dilutive funding.
- Funds will be used for working capital, product launch, and development.
- The agreement supports the commercial launch of Sofpironium Bromide gel in the US.
- Facility is structured to be drawn in multiple tranches based on milestones.
- Kreos Capital’s participation demonstrates confidence in Botanix’s business model.
- Deal strengthens Botanix’s cash position and financial flexibility.
- Funding will also support ongoing pipeline product development.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Prodigy Gold NL (PRX) ORDINARY FULLY PAID |
Materials |
$19 |
Proposed issue of securities - PRX
|
10 Jun 2025 8:39AM |
$0.003 |
$0.056 |
risen by
2,140%
|
|
| Winchester Energy Limited (WEL) ORDINARY FULLY PAID |
Energy |
$3 |
Receipt of s249D Notice
|
10 Jun 2025 8:39AM |
$0.002 |
$0.002 |
fallen by
0%
|
|
| News Corporation (NWS) CLASS B VOTING COMMON STOCK-CDI 1:1 |
Communication Services |
$1,945 |
Appendix 3C
|
10 Jun 2025 8:38AM |
$49.300 |
$44.970 |
fallen by
8.78%
|
|
| Jameson Resources Limited (JAL) ORDINARY FULLY PAID |
Materials |
$55 |
Share Issue and Cleansing Notice
|
10 Jun 2025 8:38AM |
$0.040 |
$0.074 |
risen by
85%
|
|
| News Corporation (NWS) CLASS B VOTING COMMON STOCK-CDI 1:1 |
Communication Services |
$1,945 |
Appendix 3C
|
10 Jun 2025 8:38AM |
$49.300 |
$44.970 |
fallen by
8.78%
|
|
| Waypoint REIT Limited (WPR) FULLY PAID ORDINARY/UNITS STAPLED SECURITIES |
Real Estate |
$1,743 |
Update - Notification of buy-back - WPR
|
10 Jun 2025 8:38AM |
$2.630 |
$2.670 |
risen by
1.52%
|
|
| Aura Energy Limited (AEE) ORDINARY FULLY PAID |
Energy |
$157 |
Aura strengthens executive team to drive Tiris development
|
10 Jun 2025 8:38AM |
$0.135 |
$0.175 |
risen by
29.63%
|
|
| Ironbark Balanced Income Limited (IBC) ORDINARY FULLY PAID |
Financials |
$45 |
Update - Notification of buy-back - IBC
|
10 Jun 2025 8:38AM |
$0.440 |
$0.440 |
fallen by
0%
|
|
| Optiscan Imaging Limited (OIL) ORDINARY FULLY PAID |
Health Care |
$110 |
Optiscan Reveals InSpecta Device for Veterinary Medicine
|
10 Jun 2025 8:38AM |
$0.115 |
$0.105 |
fallen by
8.70%
|
|
OIL - Price-sensitive ASX Announcement
Full Release
Key Points
- Optiscan Imaging Limited has launched the InSpectraâ„¢ device for use in veterinary medicine.
- The device utilizes confocal endomicroscopy to enable real-time cellular imaging for veterinarians.
- It targets equine, companion animal, and exotic animal sectors, supporting diagnostics and research.
- The launch is part of a strategic initiative to leverage Optiscan's technology in new markets.
- There is a significant addressable global market in veterinary medicine for such imaging solutions.
- Initial commercialization efforts will focus on Australia with plans for global expansion.
- The move aligns with Optiscan's broader goal to diversify its technology applications and revenue streams.
- InSpectraâ„¢ is positioned as a minimally invasive, advanced diagnostic tool to improve veterinary patient outcomes.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| TrivarX Ltd (TRI) ORDINARY FULLY PAID |
Health Care |
$20 |
Proposed issue of securities - TRI
|
10 Jun 2025 8:38AM |
$0.010 |
$0.017 |
risen by
70%
|
|
| Titan Minerals Limited (TTM) ORDINARY FULLY PAID |
Materials |
$244 |
Dynasty Drilling Continues to Deliver Results
|
10 Jun 2025 8:38AM |
$0.395 |
$0.850 |
risen by
115.19%
|
|
TTM - Price-sensitive ASX Announcement
Full Release
Key Points
- Titan Minerals Limited released new high-grade gold and silver assay results from the Dynasty Gold Project.
- Drilling has expanded the known mineralized footprint and confirmed mineralization continuity at depth and along strike.
- Multiple mineralized structures have been identified, supporting the geological model.
- Recent results will assist in resource estimation and drive future exploration activities.
- Operational updates include environmental and community engagement progress.
- The company is focused on advancing Dynasty toward development through systematic drilling and resource growth.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Native Mineral Resources Holdings Limited (NMR) ORDINARY FULLY PAID |
Materials |
$66 |
NMR targets Blackjack first gold pour in July 2025
|
10 Jun 2025 8:38AM |
$0.195 |
$0.066 |
fallen by
66.15%
|
|
| Dyno Nobel Limited (DNL) ORDINARY FULLY PAID |
Materials |
$5,853 |
Update - Notification of buy-back - DNL
|
10 Jun 2025 8:38AM |
$2.630 |
$3.275 |
risen by
24.52%
|
|
| Firebrick Pharma Limited (FRE) ORDINARY FULLY PAID |
Health Care |
$13 |
Nasodine Phase 3 Common Cold Trial Published
|
10 Jun 2025 8:38AM |
$0.067 |
$0.052 |
fallen by
22.39%
|
|
| RocketDNA Ltd (RKT) ORDINARY FULLY PAID |
Information Technology |
$26 |
Release of Securities from Voluntary Escrow
|
10 Jun 2025 8:37AM |
$0.011 |
$0.023 |
risen by
109.09%
|
|
| Prodigy Gold NL (PRX) ORDINARY FULLY PAID |
Materials |
$19 |
Entitlement Offer Booklet
|
10 Jun 2025 8:37AM |
$0.003 |
$0.056 |
risen by
2,140%
|
|
PRX - Price-sensitive ASX Announcement
Full Release
Key Points
- Prodigy Gold NL (PRX) is undertaking a fully underwritten 1 for 3.7 pro-rata non-renounceable entitlement offer to raise approximately $2.4 million.
- The offer price is $0.036 per new share, representing a discount to the last closing price and the 5-day volume weighted average price prior to the announcement.
- The entitlement offer is underwritten by Canaccord Genuity (Australia) Limited.
- Funds raised will be used primarily for exploration activities at the Lake Mackay Project, as well as working capital and costs of the offer.
- Eligible shareholders are those on the record date with registered addresses in Australia or New Zealand.
- The offer is non-renounceable, meaning entitlements cannot be traded or sold on the ASX.
- Directors and related parties may participate up to their entitlement, subject to shareholder approval if required.
- New shares issued under the offer will rank equally with existing shares from their date of issue.
- The document outlines key risks associated with the offer, including exploration risks, funding risks, and market risks.
- Tax implications of participating in the offer are discussed and shareholders are advised to consult tax advisors.
- A detailed timetable for the offer process, including key dates for opening, closing, and allotment of shares, is provided.
- The booklet provides instructions to shareholders on how to accept their entitlement and submit applications.
- Contact details for the share registry and company are included for shareholder enquiries.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Imricor Medical Systems Inc (IMR) CDI 1:1 US PERSON PROHIBITED EXCLUDING QIB |
Health Care |
$473 |
Imricor Receives CE Mark Approval for NorthStar
|
10 Jun 2025 8:37AM |
$1.660 |
$1.475 |
fallen by
11.14%
|
|
IMR - Price-sensitive ASX Announcement
Full Release
Key Points
- Imricor received CE Mark approval for NorthStarâ„¢ 3D Mapping System.
- Approval allows commercial sale in the European Union and CE Mark-accepting markets.
- NorthStar is used for real-time 3D mapping during cardiac ablation in MRI environments.
- Aims to advance MRI-guided electrophysiology with improved safety and workflow.
- System integrates with Imricor's Advantage-MRâ„¢ EP Recorder/Stimulator and Vision-MRâ„¢ Ablation Catheter.
- Compatible with Siemens Healthineers' MRI platform.
- CE Mark approval follows successful clinical evaluations.
- Represents a major milestone for Imricor's European expansion.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Computershare Limited (CPU) ORDINARY FULLY PAID |
Industrials |
$19,885 |
Update - Notification of buy-back - CPU
|
10 Jun 2025 8:37AM |
$41.080 |
$34.380 |
fallen by
16.31%
|
|